Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Bone Biologics Corporation

Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
Bone Biologics Announces Closing of $2.0 Million Public Offering
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
Bone Biologics Announces Pricing of $2.0 Million Public Offering
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
Bone Biologics Reports Progress With NB1 Clinical Program
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
Bone Biologics Announces 1-for-8 Reverse Stock Split
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG BBLGW
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
Bone Biologics Prices $5.0 Million Underwritten Public Offering
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
Bone Biologics Effects 1-for-30 Reverse Stock Split
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
Bone Biologics CEO Issues Letter to Stockholders
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
CORRECTING and REPLACING Bone Biologics Prices $5,100,000 Underwritten Public Offering
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
Bone Biologics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
Bone Biologics to Present at the H.C. Wainwright BioConnect Virtual Conference
From Bone Biologics Corporation
Via Business Wire
Tickers BBLG
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.